The potential risks and benefits of insulin treatment in hyperglycaemic preterm neonates

Preterm hyperglycaemia in the first 2weeks of life is common under 29weeks gestation and is associated with increased mortality and morbidity. While the definition of hyperglycaemia is reasonably consistent (>8mmol/L) the treatment threshold varies widely in clinical practice. Insulin therapy is the most common approach despite international guidance urging caution because of hypoglycaemia. Significant hypoglycaemia is unusual outside studies targeting normoglycaemia. Insulin treatment also forms part of a nutritional strategy aiming to optimise early protein and energy intake so minimising the risk of preterm postnatal growth failure.
Source: Early Human Development - Category: Perinatology & Neonatology Authors: Source Type: research